Open Payments

CLINICAL RESEARCH CONNECTIONS

Type
Non-covered entity
Where
JONESBORO, AR
Received
$609,643 in 193 records, 2020 to 2022 ($0 general, $609,643 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2022Research payment13$15,664
2021Research payment74$181,701
2020Research payment106$412,277

By company

CompanyRecordsAmountYears
GlaxoSmithKline, LLC.193$609,6432020–2022

By nature of payment

NatureRecordsAmount
Research payment193$609,643

Records

DateCompanyAmountNatureFormProductStudyYear
2022-06-29GlaxoSmithKline, LLC.$128Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2022
2022-05-25GlaxoSmithKline, LLC.$3,875Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2022
2022-05-25GlaxoSmithKline, LLC.$2,556Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2022
2022-05-06GlaxoSmithKline, LLC.$685Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2022
2022-03-25GlaxoSmithKline, LLC.$1,552Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2022
2022-03-25GlaxoSmithKline, LLC.$1,474Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2022
2022-02-04GlaxoSmithKline, LLC.$406Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2022
2022-01-28GlaxoSmithKline, LLC.$1,724Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2022
2022-01-19GlaxoSmithKline, LLC.$1,466Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2022
2022-01-19GlaxoSmithKline, LLC.$634Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2022
2022-01-19GlaxoSmithKline, LLC.$617Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2022
2022-01-19GlaxoSmithKline, LLC.$316Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2022
2022-01-19GlaxoSmithKline, LLC.$226Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2022
2021-12-17GlaxoSmithKline, LLC.$17,823Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-12-17GlaxoSmithKline, LLC.$7,281Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-12-16GlaxoSmithKline, LLC.$2,534Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-12-09GlaxoSmithKline, LLC.$2,240Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-12-08GlaxoSmithKline, LLC.$2,048Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-12-08GlaxoSmithKline, LLC.$153Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-12-02GlaxoSmithKline, LLC.$240Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-11-27GlaxoSmithKline, LLC.$3,698Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-11-24GlaxoSmithKline, LLC.$677Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-11-24GlaxoSmithKline, LLC.$653Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-11-24GlaxoSmithKline, LLC.$399Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-11-23GlaxoSmithKline, LLC.$1,000Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-11-18GlaxoSmithKline, LLC.$3,609Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-11-18GlaxoSmithKline, LLC.$1,813Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-11-18GlaxoSmithKline, LLC.$219Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-11-18GlaxoSmithKline, LLC.$113Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-11-15GlaxoSmithKline, LLC.$7,500Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-11-15GlaxoSmithKline, LLC.$1,000Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-11-11GlaxoSmithKline, LLC.$11,107Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-11-09GlaxoSmithKline, LLC.$1,000Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-11-01GlaxoSmithKline, LLC.$3,000Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-11-01GlaxoSmithKline, LLC.$1,000Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-10-15GlaxoSmithKline, LLC.$5,663Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-10-15GlaxoSmithKline, LLC.$3,850Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-10-15GlaxoSmithKline, LLC.$3,850Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-10-15GlaxoSmithKline, LLC.$901Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-10-15GlaxoSmithKline, LLC.$704Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-10-15GlaxoSmithKline, LLC.$642Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-10-15GlaxoSmithKline, LLC.$640Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-09-25GlaxoSmithKline, LLC.$930Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-09-23GlaxoSmithKline, LLC.$339Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-09-16GlaxoSmithKline, LLC.$339Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-08-25GlaxoSmithKline, LLC.$1,280Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-08-19GlaxoSmithKline, LLC.$1,131Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-08-14GlaxoSmithKline, LLC.$515Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-08-12GlaxoSmithKline, LLC.$1,000Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-08-07GlaxoSmithKline, LLC.$1,280Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-08-07GlaxoSmithKline, LLC.$1,280Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-08-07GlaxoSmithKline, LLC.$1,280Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-08-07GlaxoSmithKline, LLC.$1,280Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-08-07GlaxoSmithKline, LLC.$1,280Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-08-07GlaxoSmithKline, LLC.$1,280Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-07-28GlaxoSmithKline, LLC.$280Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-07-28GlaxoSmithKline, LLC.$280Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-07-28GlaxoSmithKline, LLC.$280Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-07-28GlaxoSmithKline, LLC.$280Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-07-28GlaxoSmithKline, LLC.$280Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-07-28GlaxoSmithKline, LLC.$280Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-07-27GlaxoSmithKline, LLC.$1,017Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-07-19GlaxoSmithKline, LLC.$3,850Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-07-08GlaxoSmithKline, LLC.$377Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-07-08GlaxoSmithKline, LLC.$339Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-07-08GlaxoSmithKline, LLC.$339Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-07-02GlaxoSmithKline, LLC.$6,095Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-07-02GlaxoSmithKline, LLC.$4,911Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-07-02GlaxoSmithKline, LLC.$4,828Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-07-02GlaxoSmithKline, LLC.$1,017Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-07-02GlaxoSmithKline, LLC.$725Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-06-20GlaxoSmithKline, LLC.$9,404Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-06-03GlaxoSmithKline, LLC.$13,970Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-05-26GlaxoSmithKline, LLC.$1,280Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-05-26GlaxoSmithKline, LLC.$256Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-04-15GlaxoSmithKline, LLC.$6,935Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-04-15GlaxoSmithKline, LLC.$1,017Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-04-08GlaxoSmithKline, LLC.$2,848Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-04-08GlaxoSmithKline, LLC.$806Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-03-18GlaxoSmithKline, LLC.$1,536Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-03-18GlaxoSmithKline, LLC.$307Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-02-25GlaxoSmithKline, LLC.$8,697Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-02-21GlaxoSmithKline, LLC.$6,958Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-02-18GlaxoSmithKline, LLC.$1,696Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-02-18GlaxoSmithKline, LLC.$377Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-02-18GlaxoSmithKline, LLC.$339Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2021-01-06GlaxoSmithKline, LLC.$1,508Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2021
2020-12-24GlaxoSmithKline, LLC.$8,722Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-12-19GlaxoSmithKline, LLC.$2,618Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-12-17GlaxoSmithKline, LLC.$6,095Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-12-17GlaxoSmithKline, LLC.$3,479Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-12-17GlaxoSmithKline, LLC.$1,095Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-12-17GlaxoSmithKline, LLC.$876Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-12-15GlaxoSmithKline, LLC.$1,885Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-12-15GlaxoSmithKline, LLC.$1,844Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-12-15GlaxoSmithKline, LLC.$1,463Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-12-15GlaxoSmithKline, LLC.$1,164Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-12-15GlaxoSmithKline, LLC.$1,164Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-12-15GlaxoSmithKline, LLC.$811Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-12-15GlaxoSmithKline, LLC.$811Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-12-15GlaxoSmithKline, LLC.$811Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-12-15GlaxoSmithKline, LLC.$811Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-12-15GlaxoSmithKline, LLC.$811Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-12-15GlaxoSmithKline, LLC.$811Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-12-15GlaxoSmithKline, LLC.$811Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-12-15GlaxoSmithKline, LLC.$811Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-12-15GlaxoSmithKline, LLC.$811Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-12-15GlaxoSmithKline, LLC.$811Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-12-15GlaxoSmithKline, LLC.$811Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-12-15GlaxoSmithKline, LLC.$725Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-12-15GlaxoSmithKline, LLC.$725Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-12-15GlaxoSmithKline, LLC.$557Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-12-15GlaxoSmithKline, LLC.$377Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-12-15GlaxoSmithKline, LLC.$282Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-11-23GlaxoSmithKline, LLC.$200Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-09-25GlaxoSmithKline, LLC.$1,972Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-09-25GlaxoSmithKline, LLC.$1,687Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-09-23GlaxoSmithKline, LLC.$3,594Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-09-23GlaxoSmithKline, LLC.$1,095Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-09-09GlaxoSmithKline, LLC.$317Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-09-02GlaxoSmithKline, LLC.$5,632Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-09-02GlaxoSmithKline, LLC.$4,202Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-09-02GlaxoSmithKline, LLC.$3,053Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-09-02GlaxoSmithKline, LLC.$1,696Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-09-02GlaxoSmithKline, LLC.$901Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-09-02GlaxoSmithKline, LLC.$678Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-09-02GlaxoSmithKline, LLC.$377Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-08-21GlaxoSmithKline, LLC.$8,193Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-08-21GlaxoSmithKline, LLC.$6,071Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-08-21GlaxoSmithKline, LLC.$4,564Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-08-21GlaxoSmithKline, LLC.$1,357Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-08-19GlaxoSmithKline, LLC.$17,688Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-08-19GlaxoSmithKline, LLC.$7,412Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-08-19GlaxoSmithKline, LLC.$6,955Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-08-19GlaxoSmithKline, LLC.$5,116Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-08-19GlaxoSmithKline, LLC.$2,207Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-08-19GlaxoSmithKline, LLC.$634Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-08-14GlaxoSmithKline, LLC.$704Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-08-05GlaxoSmithKline, LLC.$7,566Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-08-05GlaxoSmithKline, LLC.$4,396Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-08-05GlaxoSmithKline, LLC.$2,160Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-08-05GlaxoSmithKline, LLC.$1,973Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-08-05GlaxoSmithKline, LLC.$1,328Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-08-05GlaxoSmithKline, LLC.$1,244Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-07-29GlaxoSmithKline, LLC.$3,585Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-07-28GlaxoSmithKline, LLC.$725Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-06-18GlaxoSmithKline, LLC.$2,848Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-06-09GlaxoSmithKline, LLC.$3,850Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-06-04GlaxoSmithKline, LLC.$192Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-06-03GlaxoSmithKline, LLC.$728Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-05-15GlaxoSmithKline, LLC.$704Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-05-14GlaxoSmithKline, LLC.$5,912Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-05-01GlaxoSmithKline, LLC.$512Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-04-29GlaxoSmithKline, LLC.$6,074Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-04-28GlaxoSmithKline, LLC.$2,302Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-04-22GlaxoSmithKline, LLC.$3,632Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-04-17GlaxoSmithKline, LLC.$26,143Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-04-17GlaxoSmithKline, LLC.$9,912Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-04-17GlaxoSmithKline, LLC.$394Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-04-16GlaxoSmithKline, LLC.$1,408Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-04-16GlaxoSmithKline, LLC.$225Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-04-14GlaxoSmithKline, LLC.$2,630Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-04-09GlaxoSmithKline, LLC.$37,017Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-04-09GlaxoSmithKline, LLC.$3,179Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-04-09GlaxoSmithKline, LLC.$1,100Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-04-07GlaxoSmithKline, LLC.$1,504Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-04-03GlaxoSmithKline, LLC.$256Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-04-01GlaxoSmithKline, LLC.$3,520Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-04-01GlaxoSmithKline, LLC.$2,112Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-04-01GlaxoSmithKline, LLC.$912Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-04-01GlaxoSmithKline, LLC.$256Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-03-12GlaxoSmithKline, LLC.$576Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-02-20GlaxoSmithKline, LLC.$1,114Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-02-20GlaxoSmithKline, LLC.$741Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-02-18GlaxoSmithKline, LLC.$10,350Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-02-18GlaxoSmithKline, LLC.$7,500Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-02-18GlaxoSmithKline, LLC.$493Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-02-11GlaxoSmithKline, LLC.$32,066Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-02-11GlaxoSmithKline, LLC.$14,314Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-02-11GlaxoSmithKline, LLC.$5,198Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-02-11GlaxoSmithKline, LLC.$1,843Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-02-11GlaxoSmithKline, LLC.$1,455Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-02-04GlaxoSmithKline, LLC.$14,176Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-02-04GlaxoSmithKline, LLC.$268Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-02-01GlaxoSmithKline, LLC.$283Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-02-01GlaxoSmithKline, LLC.$283Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-02-01GlaxoSmithKline, LLC.$270Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-02-01GlaxoSmithKline, LLC.$270Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-01-28GlaxoSmithKline, LLC.$12,104Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-01-28GlaxoSmithKline, LLC.$11,115Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-01-28GlaxoSmithKline, LLC.$4,516Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-01-21GlaxoSmithKline, LLC.$8,500Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020
2020-01-09GlaxoSmithKline, LLC.$16,212Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P2020

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Craighead CountyJonesboro city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Jonesboro, AR, county Craighead County, AR, state Arkansas; placed by its city name.

MeasurePlace (city or town)
Jonesboro, AR
County
Craighead County, AR
State
Arkansas
Population B0100380,137113,2493,049,391
Population, 2020 census P178,576111,2313,011,524
Median age B0100233.934.538.5
Under 18 B0100124.0%25.2%23.1%
65 and over B0100114.2%13.9%17.6%
Households B1100131,91344,4371,205,987
Foreign born B050024.6%3.7%5.4%
Median household income B19013$55,424$59,548$60,773
Median family income B19113$72,057$75,703$76,968
Per capita income B19301$33,544$33,774$34,225
Poverty rate B1700122.8%20.1%16.0%
Unemployment rate B230256.3%5.6%4.9%
Civilian labor force B2302538,91255,5351,411,269
Mean commute (minutes) B0801318.019.622.5
Bachelor's degree or higher B1500331.8%29.7%25.7%
Housing units B2500135,00248,8851,394,673
Owner-occupied B2500354.3%60.1%66.4%
Renters B2500345.7%39.9%33.6%
Median home value B25077$223,200$210,400$188,000
Median gross rent B25064$956$958$947
White, not Hispanic B0300263.0%70.8%67.4%
Black B0300222.7%16.6%14.6%
Hispanic or Latino B030027.5%6.3%9.0%
Asian B030021.6%1.2%1.6%
American Indian and Alaska Native B030020.2%0.2%0.3%

Economy now FRED unemployment 3.9% in Sep 2026 (4.2% a year earlier); per capita personal income $61,697 in 2025, up 31% in five years (+5.2% after inflation); Unemployment rate: 3.9% in Sep 2016 to 3.8% in Oct 2026; low 2.9%, high 10.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Jonesboro, AR.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.